Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
Erika Bocanegra, Director of HTC Business Development and Community Engagement at Luskin Orthopaedic Institute for Children, Lifespan Orthopaedic HTC, shared CHES Foundation, Inc.‘s post on LinkedIn:
“When I first started in the bleeding disorders space 25 years ago, many of the treatment options available today were hard to imagine.
Fast forward to today, and we we’ve witnessed incredible advances, from non-factor therapies and extended half-life products to gene therapy and more personalized approaches to care.
It’s been inspiring to watch the field evolve and, more importantly, to see the positive impact these innovations have had on the lives of patients and families.
Excited to see what the future holds!”
CHES Foundation, Inc. shared a post on LinkedIn:
“HYMPAVZI is now approved for people with hemophilia A or B ages 12+ with inhibitors, as well as children ages 6–11 with or without inhibitors.
This milestone also makes HYMPAVZI the first subcutaneous non-factor therapy available for children with hemophilia B ages 6–11.”
Stay updated with Hemostasis Today.
-
Jul 17, 2026, 23:05Leonardo Roever: New Perspectives on Thromboinflammation in Acute Ischemic Stroke
-
Jul 17, 2026, 22:36Maeva May: Start Your Stroke Research Career with a Stroke Association Fellowship
-
Jul 17, 2026, 20:19Thomas Muenzel: Proud to Deliver the Sylviane Lévy-Toledano Memorial Plenary Keynote Lecture at ISTH 2026
-
Jul 17, 2026, 20:16Karin Leiderman: Proud of Jamie Madrigal for Receiving the JTH Editors’ Award
-
Jul 17, 2026, 20:14Lily Bull: Presenting New Research and Building Connections at ISTH 2026
-
Jul 17, 2026, 20:12Modern Concepts in Traumatic Disseminated Intravascular Coagulation – JTH
-
Jul 17, 2026, 20:10Nahid A. Qushmaq: Science, Collaboration, and Inspiration at ISTH 2026
-
Jul 17, 2026, 18:20Sarah Jones: Bringing Vessel-on-a-Chip Research to ISTH 2026
-
Jul 17, 2026, 18:06Virginia Barras Sánchez: United by a Commitment to Hemophilia at ISTH 2026